AstraZeneca: CHMP Recommends Enhertu For Approval In The EU

AstraZeneca and Daiichi Sankyo's Enhertu received a positive CHMP recommendation for European Union approval as adjuvant monotherapy for adults with resected HER2-positive breast cancer with residual invasive disease. The recommendation advances a potential EU label expansion for Enhertu in an earlier-stage breast-cancer setting, subject to a final European Commission decision.